Company: Unique Flower LLC
Patent Number: 12697344
Title: Therapeutic compositions, components and methods of preparation and use thereof
Innovation in Cannabinoid Therapeutics
The innovation detailed in this patent is founded on the highly specific and reproducible formulation of therapeutic botanical components. By strictly controlling the weight percentages of tetrahydrocannabinol (THC), cannabidiol (CBD), and targeted terpenes, specifically beta-Myrcene and Ocimene 2, the inventors have developed a specialized dosage form. This precise combination standardizes the therapeutic delivery of these compounds, which is necessary for treating complex conditions such as inflammation and neurological disorders with consistent clinical efficacy. Rather than relying on generic extractions, this invention provides a controlled pharmaceutical approach to plant based medicine.
Swanson Reed Patent of the Month
This invention was awarded the Patent of the Month for the state of Oregon for September 2026 by Swanson Reed due to its rigorous technical approach to therapeutic compositions. The award recognizes the objective technical merit and systematic formulation process required to transition raw extracts into reliable, repeatable dosage forms. This patent represents a measurable advancement in standardizing compounds for medical use, aligning with the ongoing agricultural and life sciences research within the state of Oregon.
Eligibility for U.S. R&D Tax Credits
The practical applications of this patent involve extensive developmental work that may qualify for the Research and Development tax credit in the United States. Under Internal Revenue Code Section 41, qualified research activities must involve overcoming technical uncertainties through a process of experimentation grounded in the hard sciences. Developing a stable formulation that maintains specific ratios of volatile terpenes and cannabinoids requires iterative testing, analytical chemistry, and clinical evaluations. The expenditures related to the engineering, compounding, and testing of these therapeutic compositions meet the strict criteria for federal and state tax incentives, providing a valuable financial pathway to support further pharmaceutical development.
